NV-104

N/A

Report date: 2023/07/17 18:06:28

Base Information

Drug NameNV-104
Drug Alias NameB7H3/irinotecan nanoparticlesNV-104NV104
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA topoisomerase inhibitorsAnti-CD276
TargetsDNA topoisomeraseCD276 antigen
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNanovalent Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A